What is Asher Biotherapeutics?
Founded in 2019 and headquartered in South San Francisco, Asher Biotherapeutics is a biotechnology firm dedicated to the development of precisely targeted immunotherapies. The company's core innovation lies in its cis-targeting platform, which is engineered to enable the selective activation of specific immune cell types. By focusing on this mechanism, Asher Biotherapeutics addresses the critical limitations of traditional, pleiotropic immunotherapies that often act on multiple cell types, thereby increasing efficacy while minimizing off-target toxicity. This technological edge positions the company at the forefront of oncology and immunology research, providing a robust foundation for addressing complex, high-unmet-need conditions.
How much funding has Asher Biotherapeutics raised?
Asher Biotherapeutics has raised a total of $218M across 3 funding rounds:
Series A
$55M
Series B
$108M
Series C
$55M
Series A (2021): $55M with participation from MBC BioLabs, Third Rock Ventures, Y Combinator, Invus, and Boxer Capital
Series B (2021): $108M led by Janus Henderson Investors, Logos Capital, Wellington Management Company, and RA Capital Management
Series C (2024): $55M supported by Bristol-Myers Squibb, AstraZeneca, and RA Capital Management
Key Investors in Asher Biotherapeutics
Bristol-Myers Squibb
A global biopharmaceutical organization with deep expertise in oncology and immunoscience, focused on developing innovative medications for serious patient needs.
AstraZeneca
A science-led biopharmaceutical company that invests heavily in research and development across oncology, immunology, and rare diseases to improve patient outcomes.
RA Capital Management
A multi-stage investment manager specializing in evidence-based investing in life science companies, utilizing its TechAtlas think tank to support scientific innovation.
What's next for Asher Biotherapeutics?
Following its recent major strategic investment, Asher Biotherapeutics is well-positioned to accelerate its clinical development programs. The company's trajectory, marked by a series of successful financing rounds from Series A through Series C, indicates a clear transition from foundational research to advanced clinical validation. Moving forward, the firm is expected to leverage its strengthened balance sheet to expand its pipeline, deepen its research capabilities, and potentially pursue further collaborative alliances with global biopharmaceutical leaders. The focus remains on translating its cis-targeting scientific breakthroughs into tangible patient outcomes, ensuring that the company remains a pivotal player in the evolving biotechnology ecosystem.
See full Asher Biotherapeutics company page
